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A B S T R A C T
Purpose
Bevacizumab improves progression-free survival but not overall survival in patients with metastatic
breast cancer. E5103 tested the effect of bevacizumab in the adjuvant setting in patientswith human
epidermal growth factor receptor 2–negative disease.
Patients and Methods
Patients were assigned 1:2:2 to receive placebo with doxorubicin and cyclophosphamide (AC)
followed by weekly paclitaxel (arm A), bevacizumab only during AC and paclitaxel (arm B), or
bevacizumab during AC and paclitaxel followed by bevacizumab monotherapy for 10 cycles (arm C).
Random assignment was stratified and bevacizumab dose adjusted for choice of AC schedule.
Radiation and hormonal therapy were administered concurrently with bevacizumab in arm C. The
primary end point was invasive disease–free survival (IDFS).
Results
Four thousand nine hundred ninety-four patients were enrolled. Median age was 52 years; 64% of
patients were estrogen receptor positive, 27%were lymph node negative, and 78% received dose-
dense AC. Chemotherapy-associated adverse events including myelosuppression and neuropathy
were similar across all arms. Grade $ 3 hypertension was more common in bevacizumab-treated
patients, but thrombosis, proteinuria, and hemorrhagewere not. The cumulative incidence of clinical
congestive heart failure at 15 months was 1.0%, 1.9%, and 3.0% in arms A, B, and C, respectively.
Bevacizumab exposure was less than anticipated, with approximately 24% of patients in arm B and
approximately 55% of patients in arm C discontinuing bevacizumab before completing planned
therapy. Five-year IDFS was 77% (95% CI, 71% to 81%) in arm A, 76% (95% CI, 72% to 80%) in
arm B, and 80% (95% CI, 77% to 83%) in arm C.
Conclusion
Incorporation of bevacizumab into sequential anthracycline- and taxane-containing adjuvant therapy
does not improve IDFS or overall survival in patients with high-risk human epidermal growth factor
receptor 2–negative breast cancer. Longer duration bevacizumab therapy is unlikely to be feasible
given the high rate of early discontinuation.
J Clin Oncol 36:2621-2629. © 2018 by American Society of Clinical Oncology
INTRODUCTION
Over the past three decades, substantial labora-
tory and indirect clinical evidence has accumu-
lated to support the central role of angiogenesis in
breast cancer progression.1 This nascent vascular
network provides a novel opportunity for therapy.
The vascular endothelial growth factor (VEGF) is
a potent stimulator of angiogenesis2 and is in-
versely correlated with overall survival (OS).3,4
Bevacizumab, a monoclonal antibody that recog-
nizes all isoforms of VEGF-A, improves response
rate and progression-free survival, although not
OS, when combined with chemotherapy in pa-
tients with metastatic breast cancer lacking over-
expression of the human epidermal growth factor 2
(HER2).5-8
As tumors progress, the number of proangio-
genic peptides produced increases.9We hypothesized
that the most successful clinical application of an-
giogenesis inhibitors would be in patients with
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micrometastatic rather than macrometastatic disease, which is to
say in the adjuvant setting. We designed E5103 to test that hy-
pothesis, incorporating bevacizumab into sequential anthracy-
cline- and taxane-containing adjuvant therapy.
PATIENTS AND METHODS
Patient Eligibility
Patients must have had adenocarcinoma of the breast with a sub-
stantial risk of systemic recurrence on the basis of at least one of the
following factors: involvement of at least one axillary or internal mammary
lymph node on routine hematoxylin and eosin staining; estrogen receptor
(ER)–negative tumor . 1 cm; ER-positive tumor . 5 cm; or ER-positive
tumor. 2 cm with an Oncotype DX Recurrence Score (Genomic Health,
Redwood City, CA)$ 11. Patients had to have completed definitive breast
surgery. 28 days and# 84 days from the start of protocol therapy; axillary
dissection was encouraged but not required for patients with an involved
sentinel node. Patients with synchronous bilateral breast cancer were
eligible if the higher TNM stage tumor met the eligibility criteria. All
patients had to have adequate renal, hepatic, and hematologic function.
Left ventricular ejection fraction (LVEF) greater than the institutional
lower limit of normal (LLN) was required.
Patients with HER2-positive disease, defined as 3+ by immunohis-
tochemistry or gene amplification by fluorescence in situ hybridization that
would support treatment with HER2-targeted therapy (ie, HER2:CEP17
ratio $ 2.0), were excluded. Patients could not have received prior cy-
totoxic chemotherapy or hormonal therapy for this breast cancer. Prior
treatment with an anthracycline, anthracenedione, or taxane for any
condition was not allowed. In addition, patients were excluded if they had
a major surgery within 4 weeks, nonhealing wound or fracture, infection
requiring parenteral antibiotics, or clinically significant cardiovascular
disease. Therapeutic anticoagulation, regular nonsteroidal anti-inflammatory
medication, and aspirin (. 325 mg/d) were prohibited, but prophylactic
low-dose anticoagulants were permitted.
The Eastern Cooperative Oncology Group–American College of
Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group
coordinated the study in collaboration with the North Central Cancer
Treatment Group and Cancer and Leukemia Group B. Local institutional
review boards approved the protocol, and patients provided written in-
formed consent before screening.
Treatment Plan
All patients received doxorubicin and cyclophosphamide (AC) fol-
lowed by paclitaxel weekly for 12 weeks as in the prior E1199 trial.10 AC
could be administered in a classic (every 3 weeks) or a dose-dense (every
2 weeks) schedule11 on the basis of investigator discretion; bevacizumab
dose was adjusted for choice of AC schedule (patients receiving classic AC
received bevacizumab 15 mg/kg; patients receiving dose-dense AC received
bevacizumab 10 mg/kg). Placebo (arm A) or bevacizumab (arms B and C)
was administered concurrently with chemotherapy. All patients were
unblinded at week 10 of paclitaxel therapy. Patients in arm C continued
bevacizumab monotherapy (15 mg/kg every 3 weeks) for an additional
10 cycles. Radiation therapy (RT) was required for all patients treated with
breast-conserving surgery (BCS); postmastectomy RT was required for
patients with primary tumors . 5 cm or involvement of four or more
axillary lymph nodes and was allowed at the discretion of the treating
physician for all other patients. Hormonal therapy was recommended for
all patients with tumors expressing ER and/or progesterone receptors.
When indicated, RT and hormonal therapy were to commence within
6 weeks of completion of chemotherapy and were administered concur-
rently with bevacizumab for patients in arm C.
Chemotherapy dose modifications were mandated for hematologic
and nonhematologic toxicity as in E1199.10 Bevacizumab therapy was
interrupted for uncontrolled hypertension or proteinuria $ 3,500 mg in
24 hours. Bevacizumab was permanently discontinued for symptomatic
hypertension, nephrotic syndrome, venous thrombosis requiring anti-
coagulation, arterial thrombosis, serious bleeding, bowel perforation, or
wound dehiscence. Chemotherapy dose reduction did not affect bev-
acizumab treatment. However, if a chemotherapy cycle was delayed,
bevacizumab therapy was delayed to maintain concurrent administration.
If chemotherapy was permanently discontinued, patients could complete
the planned therapy with bevacizumab alone.
Safety Assessments
CBCs were assessed before each chemotherapy infusion. Serum
chemistry was required every other treatment cycle; urine protein-to-
creatinine ratio was assessed approximately every four cycles.
Bevacizumab was held and cardiac evaluation repeated in 4 weeks in
patients with an absolute decrease in LVEF$ 16% or a decrease of 10% to
15% to a value less than LLN. Bevacizumab was continued but cardiac
evaluation repeated in 4 weeks in patients with an LVEF decrease, 10% to
less than LLN. Bevacizumab was permanently discontinued in all patients
with symptomatic congestive heart failure (CHF) and those with cardiac
assessments requiring bevacizumab to be held at two consecutive or three
intermittent time points.
Definition and Assessment of Clinical CHF
Cardiac assessment with either multigated acquisition scan or
echocardiography was performed within 8 weeks before registration, on
day 1 of cycle 5, within 2 weeks of completing chemotherapy, 1 year from
study entry in all arms, and on day 1 of cycle 15 in arm C patients. A
physician-directed cardiac symptom evaluation was conducted 2 years
from entry. Clinical CHF was defined as a decline in LVEF to less than LLN
or diastolic dysfunction occurring concurrently with any of the following:
grade $ 2 lower extremity edema, grade $ 2 dyspnea, or grade 1 dyspnea
associated with an LVEF , 40%. Auscultation of an S3 gallop, bibasilar
rales, and documented cardiomegaly also constituted signs of clinical CHF.
All potential instances of clinical CHF were adjudicated by the study
primary investigator and two independent cardiologists, who were all
blinded to the treatment assignment.
Statistical Design and Monitoring
The primary end point was invasive disease–free survival (IDFS).12 A
total accrual of 4,950 patients across three arms was planned; blinded
treatment assignments were made in permuted blocks in a 1:2:2 fashion to
arm A (n = 990), arm B (n = 1,980), and arm C (n = 1,980). Random
assignment was stratified by the following: ER-positive tumor (yes or no),
lymph node involvement (negative, one to three nodes, or four or more
nodes), type of surgery and RT (BCS plus RT, BCS plus accelerated partial
breast irradiation, mastectomy and no RT, or mastectomy plus RT), and
AC schedule (classic or dose dense). A two-step hierarchical approach was
used, first testing arm C with arm A. Assuming a 5-year IDFS of 80% for
arm A (based on E119910), 2,970 patients accrued to arms A and C over
2.06 years and observed for an additional 3.14 years with 426 IDFS events
provided 80% power to detect a 25% reduction in the failure hazard rate
using a one-sided P = .025 test. Only if arm C significantly improved IDFS
relative to arm A was a comparison of arm B to arm A to be performed.
Only if both arms C and B significantly improved IDFS relative to arm A
was a comparison of arm C to arm B to be performed. O’Brien-Fleming
boundaries13 and the Jennison-Turnbull repeated CI method14 were used
to monitor for early stopping. The ECOG-ACRIN Data Safety Monitoring
Committee reviewed three planned interim outcome analyses without
stopping criteria being met. Taking these into account, the threshold for
significance for this final analysis is P , .02 (nominal, one-sided).
The Data Safety Monitoring Committee continuously monitored
safety. One of two prespecified stopping rules was met and accrual was
suspended on September 24, 2009 (six of the first 200 patients randomly
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assigned to the combined arms B and C experienced clinical CHF). After
review of safety data by ECOG-ACRIN, the Cancer Therapy Evaluation
Program, and the US Food and Drug Administration and revision of
clinical CHF risk in the consent form, accrual reopened on December 18,
2009.
Comparisons between arms were intent-to-treat analyses among all
patients. The Kaplan-Meier method was used to estimate distributions for
IDFS and OS. Cox proportional hazards models, stratified by the factors at
random assignment, were used to estimate hazard ratios and to test for
significance in outcome. Cumulative incidence curves for development of
clinical CHF and time to treatment discontinuation were generated. Two-
sided P values and 95% CIs are reported.
Role of the Sponsor
E5103 was conducted under a corporate research and development
agreement between Genentech (South San Francisco, CA) and the National
Cancer Institute (Bethesda, MD). Genentech provided bevacizumab and
partial funding but did not participate in data collection. ECOG-ACRIN
statisticians independently conducted the analyses. The lead author made
the decision to publish and wrote the article, which was then reviewed by
all authors and submitted to NCI and Genentech for comment. The
authors vouch for the completeness and accuracy of the data.
RESULTS
Four thousand nine hundred ninety-four patients were enrolled
between November 2007 and February 2011 (Fig 1). The study
arms were well balanced (Table 1). The majority had poorly
differentiated tumors larger than 2 cm with involvement of at
least one axillary lymph node. Nearly two thirds of patients had
ER-positive disease. Seventy-eight percent of patients received AC
in the dose-dense schedule.
Efficacy
In arms A, B, and C, 5-year IDFS rates were 77% (95% CI,
71% to 81%), 76% (95% CI, 72% to 80%), and 80% (95%CI, 77%
to 83%), respectively, and 5-year OS rates were 90% (95% CI, 87%
to 92%), 86% (95% CI, 83% to 88%), and 90% (95% CI, 88% to
92%), respectively (Table 2 and Figs 2A and 2B) Longer duration
bevacizumab therapy led to a favorable but nonsignificant dif-
ference in IDFS among patients with hormone receptor–negative
tumors (Fig 2C). No other clinical factors identified subsets of
patients who benefited from bevacizumab.
Adverse Events
Noncardiac chemotherapy-related toxicities were comparable
to those reported in the E119910 and C974111 trials (Table 3). Eight
percent of bevacizumab-treated patients experienced grade 3 hy-
pertension (Table 3). The increase in minor mucosal bleeding
reported in the prior adjuvant pilot trial15 was not detected in
E5103. Grade 3 or 4 hemorrhage, thromboembolic events, GI
perforation, and wound complications were uncommon adverse
events and similar across treatment arms. Bevacizumab mono-
therapy was associated with an ongoing risk of toxicity, particularly
hypertension (Table 3). The risk of treatment-related death during
or within 30 days of protocol treatment (n = 14, 0.3%) was similar
across study arms; causes included acute myelogenous leukemia
(n = 3), infection (n = 2), CNS ischemia or hemorrhage (n = 2),
pulmonary hemorrhage or fibrosis (n = 2), liver failure (n = 1),
thrombosis or embolism (n = 1), colitis (n = 1), sudden death
(n = 1), and hypotension (n = 1).
As expected from previous trials,5,15 the addition of bev-
acizumab led to a small but real increase in cardiac toxicity. At
15 months, the cumulative incidence of clinical CHF was 1.0%,
1.9%, and 3% in arms A, B, and C, respectively (Appendix Fig A1,
online only) and was not clearly related to RT or clinical risk
factors. Most patients with changes in LVEF remained asymp-
tomatic (Appendix Table A1, online only).
Drug Exposure and Discontinuation
The addition of bevacizumab reduced the ability to complete
chemotherapy, with more patients in arms B and C discontinuing
E5103: Lymph Node–Positive and High-Risk
Lymph Node–Negative Breast Cancer
Arm A
AC* + placebo for 4 cycles 
followed by paclitaxel for 12 cycles + 
placebo for 4 cycles
Arm B
AC* + bevacizumab for 4 cycles 
followed by paclitaxel for 12 cycles + 
bevacizumab for 4 cycles
Arm C
AC* + bevacizumab for 4 cycles 
followed by paclitaxel for 12 cycles + 
bevacizumab for 4 cycles
Arm D
Bevacizumab for 10 cycles
Randomly assigned 
Did not start protocol treatment 
Ineligible 
Randomly assigned 
Did not start protocol treatment 
Ineligible 
(n = 1,986)
(n = 64)
(n = 91)
Randomly assigned 
Did not start protocol treatment 
Ineligible 
(n = 1,000)
(n = 28)
(n = 45)
Registered 
Did not start maintenance 
   bevacizumab 
 (n = 1,316)
(n = 148)
(n = 1,000)
(n = 157)
(n = 79)
(n = 50)
In primary analysis 
IDFS events 
Deaths 
Median follow-up, 47.6 months
Patients who were lost or 
   refused follow-up 
(n = 1,986)
(n = 299)
(n = 159)
(n = 83)
In primary analysis
IDFS events
Deaths
Median follow-up, 47.5 months
Patients who were lost or 
   refused follow-up
(n = 2,008)
(n = 273)
(n = 144)
(n = 125)
In primary analysis
IDFS events
Deaths
Median follow-up, 47.3 months
Patients who were lost or 
   refused follow-up
(n = 2,008)
(n = 66)
(n = 92)
Fig 1. CONSORT diagram. All patients enrolled (N = 4,994) were included in efficacy analyses. All treated patients (n = 4,836) were evaluated for toxicity. AC, doxorubicin
and cyclophosphamide; IDFS, invasive disease–free survival. (*) Every 14 or 21 days per physician and patient choice.
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chemotherapy before completing the planned treatment (18.3% in
arm A v 26.3% in arm B and 28% in arm C). Forty percent of
patients (774 of 1,942 patients) who began treatment on arm C did
not proceed to bevacizumab maintenance therapy, most com-
monly as a result of patient withdrawal or refusal or treatment-
related toxicity (Fig 1 and Appendix Fig A2, online only).
DISCUSSION
The addition of bevacizumab to sequential anthracycline and
taxane adjuvant therapy did not improve IDFS or OS in this high-
risk, HER2-negative population. Although subset analyses pointed
to a potential benefit for longer duration bevacizumab in patients
with ER-negative disease, the Adjuvant Bevacizumab-Containing
Therapy in Triple-Negative Breast Cancer (BEATRICE) trial found
no benefit to adding bevacizumab to adjuvant chemotherapy in
patients with triple-negative (ER, progesterone receptor, and HER2
negative) disease,16,17 suggesting that this association is spurious.
E5103 may have been a negative study for many reasons. First,
delivery of both chemotherapy and bevacizumab may have been
inadequate. The addition of bevacizumab attenuated delivery of
chemotherapy, and early drug discontinuation severely limited
bevacizumab exposure. The overall rate of bevacizumab discon-
tinuation, particularly in patients randomly assigned to arm C
(approximately 70%), was predicted by the E2104 pilot trial.15
Although the withdrawal of US Food and Drug Administration
approval for bevacizumab in the metastatic setting may have led
some patients to discontinue therapy, most stopped as a result of an
adverse event. No single adverse event predominated, and toxicity
rarely reached grade 3 severity. In comparison, approximately 25%
to 30% of patients in the adjuvant trastuzumab trials discontinued
treatment early,18,19 whereas , 20% of patients stopped anas-
trozole during the first year of therapy.20 This may reflect less
Table 1. Patient Characteristics
Characteristic
No. of Patients (%)
Arm A (n = 1,000) Arm B (n = 1,986) Arm C (n = 2,008) Total (N = 4,994)
Median age, years (range) 51.8 (25.4-77.7) 51.7 (21.2-85.0) 51.6 (21.5-82.5) 51.7 (21.2-85.0)
ECOG PS
0 860 (86) 1,714 (86) 1,700 (85) 4,274 (86)
1 138 (14) 272 (14) 307 (15) 717 (14)
Missing 2 — 1 3
Sex
Male 5 (, 1) 10 (, 1) 8 (, 1) 23 (, 1)
Female 995 (99.5) 1,976 (99.5) 2,000 (99.5) 4,971 (99.5)
Race
White 848 (85) 1,687 (85) 1,686 (84) 4,221 (85)
African American 101 (10) 224 (11) 240 (12) 565 (11)
Asian 43 (4) 56 (3) 59 (3) 158 (3)
Other 7 (1) 11 (1) 15 (1) 33 (1)
Missing 1 8 8 17
Primary tumor size, cm
# 2 376 (38) 782 (39) 775 (39) 1,933 (39)
. 2 to # 5 521 (52) 1,007 (51) 1,024 (51) 2,552 (51)
. 5 102 (10) 194 (10) 207 (10) 503 (10)
Missing 1 3 2 6
LN involvement
Negative 259 (26) 541 (27) 563 (28) 1,363 (27)
Positive 740 (74) 1,443 (73) 1,444 (72) 3,627 (73)
Missing 1 2 1 4
Histologic grade
1 74 (8) 174 (9) 174 (9) 422 (9)
2 354 (36) 641 (33) 633 (32) 1,628 (33)
3 551 (56) 1,124 (58) 1,158 (59) 2,833 (58)
Missing 21 47 43 111
ER and PgR status
ER and PgR negative 350 (35) 717 (36) 729 (36) 1,796 (36)
ER and/or PgR positive 649 (65) 1,269 (64) 1,276 (64) 3,194 (64)
Missing 1 — 3 4
Local therapy
BCS + WBRT 395 (40) 791 (41) 789 (40) 1,975 (40)
BCS + APBI 7 (1) 19 (1) 22 (1) 48 (1)
Mastectomy 178 (18) 385 (20) 393 (20) 956 (20)
Mastectomy + RT 342 (35) 648 (33) 632 (32) 1,622 (33)
BCS/no RT 35 (3) 48 (2) 57 (3) 140 (3)
Missing 15 31 49 95
Did not start protocol therapy 28 (3) 64 (3) 66 (4) 158 (3)
Abbreviations: APBI, accelerated partial breast irradiation; BCS, breast-conserving surgery; ECOG PS, Eastern Cooperative Oncology Group performance status; ER,
estrogen receptor; LN, lymph node; PgR, progesterone receptor; RT, radiation therapy; WBRT, whole-breast radiation therapy.
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willingness of patients and treating physicians to accept bevacizumab-
specific toxicities. Because many of the bevacizumab-specific toxicities
have a constant, cumulative risk over time,21 we cannot recommend
trials exploring a longer duration of therapy.
Second, although bevacizumab targets VEGF-A, the study
population was not enriched for VEGF-A expression or any other
molecular feature. Despite repeated efforts, we lack a way to identify
patients more or less likely to benefit from bevacizumab. We have
interrogated samples collected in metastatic trials at both the genomic
and proteomic levels. Potential predictors on the basis of expression of
VEGF or its ligands, inherited polymorphisms in the VEGF-A gene,
circulating pro- and antiangiogenic peptides, and oncogene expression
have been put forth.8,22-30 Although isolated associations have been
found, overall the results have been inconsistent, lacked correction for
multiple testing, or failed in confirmatory trials. In sum, bevacizumab
has remained stubbornly undifferentiated.
When viewed within the context of similar negative trials in
patients with HER2-positive breast cancer,31 colon cancer,32,33
melanoma,34,35 and lung cancer,36 we have no choice but to con-
clude that the underlying hypothesis, namely that inhibiting VEGF
would bemost effective in the adjuvant setting, is simply wrong. How
could such compelling biology and generally positive results in the
metastatic setting give way to such uniformly negative adjuvant trials?
Microscopic disease does not have an established vasculature
and thus may be inherently resistant to anti-VEGF therapy. For
example, vascular normalization, a reduction in tumor interstitial
pressure leading to improved delivery of cytotoxic therapy,37,38
does not apply to micrometastatic disease. We have learned that
tumors establish a vasculature in at least six different ways, each
with varying sensitivity to VEGF inhibition (reviewed by Carmeliet
and Jain39). The predominant mode of vascularization and,
therefore, sensitivity to VEGF inhibition may differ in micro-
metastatic versus macrometastatic disease. Although VEGF plays
an important role in establishing the premetastatic niche (an event
that occurs before clinical diagnosis), once established, avascular
micrometastatic deposits (equivalent to the adjuvant setting) may
persist despite VEGF inhibition.40
Early enthusiasm for antiangiogenic therapy was buoyed by
claims that this was a therapy resistant to resistance.41 Multiple
mechanisms of resistance to anti-VEGF therapy have been iden-
tified, including induction of alternative angiogenic pathways,
hypoxia-mediated increases in aggressiveness, cancer stem cells
and autophagy, and compensatory recruitment of vascular pro-
genitors.42-47 Recent preclinical models suggested an increase in
metastasis with VEGF inhibition. Thankfully, that has not been
apparent clinically. Although bevacizumab has been ineffective in
the adjuvant setting, none of the reported trials suggested a dele-
terious effect.
Multiple lessons can be learned from this negative clinical
trial. First, our preclinical models were, and likely still are, in-
adequate to model the complex biology at play before the de-
velopment of overt metastases. No matter how persuasive the
biology and how convincing the results in the metastatic setting,
adjuvant trials are the final clinical laboratory.
Second, we should have taken the concerns about early dis-
continuation in the adjuvant setting more seriously. Calculating the
effect of early discontinuation on overall benefit requires knowl-
edge of both the treatment effect and the impact of duration of
therapy on that effect—factors that were unknowable when E5103
began. If future studies proceed despite concerns about feasibility,
strategies to mitigate toxicity and enhance adherence will be
crucial. Early termination of such trials if the discontinuation
Table 2. IDFS and OS
Survival Arm A (n = 1,000) Arm B (n = 1,986) Arm C (n = 2,008)
IDFS
No. of events 157 299 273
5-year IDFS, % (95% CI) 77 (71 to 81) 76 (72 to 80) 80 (77 to 83)
HR (95% CI)*
Univariate 0.87† (0.71 to 1.06) 0.95‡ (0.78 to 1.16) 0.91§ (0.77 to 1.07)
P .17 .62 .25
Multivariatek 0.84† (0.69 to 1.02) 0.93‡ (0.77 to 1.13) 0.89§ (0.76 to 1.06)
P .08 .47 .19
ER/PgR negative 0.77† (0.58 to 1.03) 1.00‡ (0.76 to 1.33) 0.77§ (0.61 to 0.98)
OS
Median follow-up, months 47.6 47.5 47.3
No. of events 79 159 144
5-year OS, % (95% CI) 90 (87 to 92) 86 (83 to 88) 90 (88 to 92)
HR (95% CI)*
Univariate 0.89† (0.68 to 1.17) 1.01‡ (0.77 to 1.33) 0.90§ (0.72 to 1.13)
P .41 .92 .36
Multivariatek 0.86† (0.66 to 1.14) 0.99‡ (0.75 to 1.30) 0.90§ (0.72 to 1.13)
P .30 .93 .36
ER/PgR negative 0.77† (0.53 to 1.12) 0.99‡ (0.69 to 1.41) 0.79§ (0.58 to 1.06)
Abbreviations: ER, estrogen receptor; HR, hazard ratio; IDFS, invasive disease–free survival; OS, overall survival; PgR, progesterone receptor.
*P values are two-sided and are based on stratified test using stratification factors at random assignment.
†Arm C v arm A: Values , 1 indicate better outcome for arm C.
‡Arm B v arm A: Values , 1 indicate better outcome for arm B.
§Arm C v arm B: Values , 1 indicate better outcome for arm C.
kAdjusted for age, ER and PgR status, nodal status, tumor size, and grade (to preserve sample size, dummy variables were included for missing disease status values).
Stratification variables for this model included type of surgery or radiotherapy and doxorubicin and cyclophosphamide schedule (classic or dose dense) but excluded ER
and nodal status because these were covariates in the model.
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Fig 2. Five-year (A) invasive disease–free survival (IDFS)
and (B) overall survival rates were similar across all treatment
arms. (C) IDFS in patients with estrogen receptor– and
progesterone receptor–negative disease. Hazard ratios for
IDFS favored bevacizumab in patients with hormone
receptor–negative tumors receiving longer duration bev-
acizumab therapy, but this difference did not reach significance.
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rate reaches a critical, albeit arbitrary, threshold should be
considered.
Some may argue that E5103 was started prematurely and that
we should have demanded more data in the metastatic setting before
embarking on such a large adjuvant trial. At the time E5103 was
designed, early survival data from E21005 were quite promising, but
the data were not final and would not have reached a threshold for
early stopping had OS been the primary end point. Preliminary
results from the Avastin Plus Docetaxel Chemotherapy (AVADO)
trial6 reported a positive but less striking improvement in
progression-free survival. Of course, once negative results are in
hand, it is easy to argue that the basis was not strong enough to
support a trial of this magnitude. In reality, we have started ad-
juvant trials with much less supporting data (eg, studying tras-
tuzumab or pembrolizumab). Even when the supporting data are
stronger andOS in themetastatic is improved, adjuvant results may
be disappointing (eg, as with lapatinib or pertuzumab). E5103
reminds us that adjuvant trials will always entail risk.
E5103 adds another cautionary note to those who have embraced
an improvement in pathologic complete response (pCR) as predictive
of longer term benefit. Four neoadjuvant trials found that adding
bevacizumab to chemotherapy in patients with HER2-negative disease
improved pCR,48-51 and with longer follow-up, one52 reported
a survival benefit. Yet, the adjuvant trials have been resolutely negative.
Is this discordance between neoadjuvant and adjuvant results an
aberration? A similar discordance was seen in trials of lapatanib53,54
and, somewould argue, pertuzumab, where the striking improvement
in pCR55 barely reached significance in the adjuvant setting.56 Indeed,
an analysis across trials did not find an association between increases
in pCR and improvements in event-free survival.57
Finally, E5103 reminds us of the importance of publically
funded research and the resulting public and private partnership.
Some may question whether public support should be granted to
a trial with registration intent. However, E5103 generated a richly
annotated biospecimen bank that, combined with ongoing follow-
up, will support important studies. Analyses embedded within
E5103 have already taught us the effect of unblinding and random
assignment to placebo in clinical trial participants58 and studied
biomarkers predictive of amenorrhea.59 Germline DNA analyses
have identified single nucleotide polymorphisms associated with
Table 3. Select Adverse Events
Adverse Event
% of Patients
Arm A (n = 972) Arm B (n = 1,922)
Arm C (bevacizumab cycles
1 to 8; n = 1,942)
Arm D (bevacizumab cycles
9 to 18 of arm C; n = 1,168)
Grade
2
Grade
3
Grade
4
Grade
5
Grade
2
Grade
3
Grade
4
Grade
5
Grade
2
Grade
3
Grade
4
Grade
5
Grade
2
Grade
3
Grade
4
Grade
5
Anemia NA NA 1 — NA NA 2 — NA NA 1 — NA NA , 1 —
Neutropenia NA NA 17 — NA NA 20 — NA NA 20 — NA NA 1 —
Febrile neutropenia NA 3 , 1 — NA 4 , 1 — NA 4 1 — NA NA — —
Thrombocytopenia NA NA , 1 — NA NA 1 — NA NA 1 — NA NA — —
Nausea NA 3 — — NA 3 — — NA 3 — — NA , 1 — —
Mucositis (oral) NA 1 , 1 — NA 3 — — NA 3 , 1 — NA — — —
Increased AST/ALT NA NA , 1 — NA NA , 1 — NA NA , 1 — NA NA , 1 —
Fatigue NA 7 , 1 — NA 10 , 1 — NA 10 , 1 — NA 3 — —
Sensory neuropathy 19 8 , 1 — 19 8 , 1 — 17 9 , 1 — 16 4 , 1 —
Arthralgia/joint pain NA 3 — — NA 2 , 1 — NA 2 , 1 — NA 3 , 1 —
Myalgia/muscle pain NA 2 , 1 — NA 2 , 1 — NA 1 , 1 — NA 2 — —
Dyspnea 5 3 , 1 — 6 3 1 — 6 3 , 1 — 2 1 , 1 —
Pneumonitis NA 1 — — NA 1 , 1 — NA 1 , 1 — NA — — —
Hypertension NA 2 , 1 — NA 8 , 1 — NA 7 , 1 — NA 11 , 1 —
Headache NA 2 — — NA 4 , 1 — NA 3 , 1 — NA 2 , 1 —
Left ventricular
diastolic dysfunction
, 1 , 1 — — 1 , 1 — — 1 , 1 — — 1 , 1 — —
Left ventricular systolic
dysfunction*
4 1 — — 5 2 , 1 — 4 2 , 1 — 5 3 , 1 —
Proteinuria 1 — — — 1 , 1 — — 1 , 1 — — 3 2 — —
Thrombosis/embolism 1 3 1 — 1 2 1 , 1 1 2 1 — 1 1 , 1 , 1
Hemorrhage (nose) , 1 — — — 1 , 1 — — 2 , 1 — — 1 , 1 — —
Hemorrhage (rectal) , 1 , 1 — — , 1 , 1 — — 1 , 1 — — , 1 , 1 — —
Colon/appendix
perforation
— , 1 — — — — , 1 — — , 1 , 1 — — — , 1 —
Wound dehiscence,
noninfectious
NA , 1 — — NA 1 — — NA 1 — — NA 1 — —
Allergic reaction NA 1 , 1 — NA 1 — — NA 1 , 1 — NA , 1 — —
CNS ischemia — — , 1 , 1 — , 1 , 1 — — , 1 , 1 — — , 1 , 1 —
CNS hemorrhage , 1 — — — , 1 — — — , 1 , 1 — , 1 — — , 1 —
Leukoencephalopathy — — — — — — , 1 — — — — — — — — —
NOTE. Worst adverse event reported per patient based on Common Terminology Criteria for Adverse Events (version 3.0). Only patients who began protocol treatment
in each arm are included in this summary. Adverse event reporting in the trial was limited to$ grade 4 hematologic events,$ grade 2 nonhematologic events for a group
of specific adverse events, and $ grade 3 nonhematologic events otherwise. All attributions were included.
Abbreviation: NA, not applicable (grade not collected for that adverse event and only appears in the table when events are present for the other reportable grades).
*Common Terminology Criteria for Adverse Events grade 3 left ventricular systolic dysfunction includes decreases in left ventricular ejection fraction to an absolute
value between 20% and 40% and/or symptoms of congestive heart failure.
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increased risk of common chemotherapy-related toxicities
including peripheral sensory neuropathy60,61 and anthracycline-
induced cardiotoxicity,62 whereas companion studies have quanti-
fied the effect of such biomarkers on physician recommendation and
patient preference for different treatments.63,64 An associated bio-
bank identified a marker for late relapse, paving the way for trials of
delayed intervention.65 These correlative studies, unlikely to have
been supported in a trial funded exclusively by industry, expand the
effect of E5103 far beyond disproving the original clinical hypothesis.
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Fig A1. Cumulative incidence of clinical congestive heart failure (CHF). Bevacizumab increased the risk of clinical CHF in a time- and exposure-dependent manner. Most
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chemotherapy. Only 29% of patients (585 of 2,008 patients) randomly assigned to arm C completed all prescribed bevacizumab therapy.
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Table A1. Sequential Assessment of LVEF
LVEF Arm A Arm B Arm C Arm D*
Baseline and cycle 5†
No. of patients 909 1,728 1,744
Median baseline LVEF, % (95% CI) 64 (49 to 87) 64 (50 to 89) 64 (50 to 85)
Median LVEF at cycle 5, % (95% CI) 63 (37 to 89) 62 (27 to 89) 62 (30 to 87)
LVEF decrease . 10%, No. (%) 69 (8) 152 (9) 172 (10)
LVEF decrease . 10% to , LLN, No. (%) 8 (1) 28 (2) 39 (2)
Baseline and EOC/cycle 9
No. of patients 865 1,715 553‡ 1,148
Median LVEF at EOC/cycle 9, % (95% CI) 61 (35 to 90) 60 (10 to 94) 60 (18 to 83) 60 (25 to 90)
LVEF decrease . 10%, No. (%) 99 (12) 306 (18) 125 (23) 168 (15)
LVEF decrease . 10% to , LLN, No. (%) 21 (2) 107 (6) 64 (12) 40 (3)
Baseline and cycle 15
No. of patients 899
Median LVEF at cycle 15, % (95% CI) 60 (30 to 83)
LVEF decrease . 10%, No. (%) 148 (16)
LVEF decrease . 10% to , LLN, No. (%) 27 (3)
Baseline and 12 months/EOB
No. of patients 683 1,382 444‡ 1,029
Median LVEF at 12 months/EOB, % (95% CI) 60 (25 to 82) 61 (35 to 85) 61 (20 to 84) 60 (23 to 84)
LVEF decrease . 10%, No. (%) 88 (13) 183 (13) 86 (19) 184 (18)
LVEF decrease . 10% to , LLN, No. (%) 21 (3) 42 (3) 36 (8) 52 (5)
Abbreviations: EOB, end of bevacizumab; EOC, end of chemotherapy; LLN, lower limit of normal; LVEF, left ventricular ejection fraction.
*Arm D includes patients randomly assigned to arm C who proceeded to bevacizumab monotherapy.
†A prespecified stopping rule that monitored for difference at cycle 5 among the first 300 patients who received protocol therapy between arms A and C or between
arms A and B plus C with respect to proportion of patients with an absolute decrease in LVEF . 10% to less than LLN was not met.
‡Patients randomly assigned to arm C who did not proceed to bevacizumab monotherapy.
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